Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left" colspan="2"> </td><td class="align_center">Undecided</td><td class="align_center">ET</td><td class="align_center">ET + CT</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left" rowspan="2">Low score</td><td class="align_center">Pregenomic plan</td><td class="align_center">10</td><td class="align_center">5</td><td class="align_center">19</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">27</td><td class="align_center">7</td></tr><tr><td class="align_left" rowspan="2">Intermediate score</td><td class="align_center">Pregenomic plan</td><td class="align_center">10</td><td class="align_center">4</td><td class="align_center">19</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">8</td><td class="align_center">25</td></tr><tr><td class="align_left" rowspan="2">High score</td><td class="align_center">Pregenomic plan</td><td class="align_center">1</td><td class="align_center">0</td><td class="align_center">7</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">0</td><td class="align_center">8</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Therapeutic plans pregenomics and postgenomics testing according to scores for 75 patients.</div>

Journal of Oncology

tab2

Table 2

Table 2: Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients 